{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T11:57:02Z","timestamp":1768046222809,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.4158\/e161376.or","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T12:14:32Z","timestamp":1476274472000},"page":"1177-1186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Variables Affecting the Long-Term Outcome of Graves Orbitopathy Following High-Dose Intravenous Glucocorticoid Pulse Therapy in Patients not Treated with Orbital Radiotherapy"],"prefix":"10.1016","volume":"22","author":[{"given":"Marenza","family":"Leo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Mautone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Ionni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Antonietta","family":"Profilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Sabini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Menconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Mazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Rocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Latrofa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Vitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Marcocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Marin\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/E161376.OR_bb0010","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMcp0806317","article-title":"Clinical practice. Graves' orbitopathy","volume":"360","author":"Bartalena","year":"2009","journal-title":"N Engl J Med"},{"key":"10.4158\/E161376.OR_bb0015","first-page":"168","article-title":"Management of Graves' ophthalmopathy: reality and perspectives","volume":"212","author":"Bartalena","year":"2000","journal-title":"Endocr Rev"},{"key":"10.4158\/E161376.OR_bb0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF03345280","article-title":"Graves' orbitopathy: state of the art and perspectives","volume":"27","author":"Bartalena","year":"2004","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/E161376.OR_bb0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.beem.2011.11.005","article-title":"Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy","volume":"26","author":"Marcocci","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.4158\/E161376.OR_bb0030","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/ncpendmet0500","article-title":"A treatment strategy for Graves' orbitopathy","volume":"3","author":"Marcocci","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.4158\/E161376.OR_bb0035","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/E161376.OR_bb0040","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40618-014-0097-2","article-title":"Extrathyroidal manifestations of Graves' disease: a 2014 update","volume":"37","author":"Bartalena","year":"2014","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/E161376.OR_bb0045","first-page":"444","article-title":"Prevalence and natural history of Graves' orbitopathy in the XXI century","volume":"36","author":"Piantanida","year":"2013","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/E161376.OR_bb0050","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/thy.2014.0475","article-title":"Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center","volume":"25","author":"Leo","year":"2015","journal-title":"Thyroid"},{"key":"10.4158\/E161376.OR_bb0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-14-0712","article-title":"Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study","volume":"172","author":"Sisti","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/E161376.OR_bb0060","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1089\/thy.2015.0061","article-title":"Age and dose are major risk factors for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' Orbitopathy","volume":"25","author":"Sisti","year":"2015","journal-title":"Thyroid"},{"key":"10.4158\/E161376.OR_bb0065","doi-asserted-by":"crossref","DOI":"10.1007\/s12020-016-0928-3","article-title":"Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy Epub ahead of print","author":"Moleti","year":"2016","journal-title":"Endocrine"},{"key":"10.4158\/E161376.OR_bb0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"key":"10.4158\/E161376.OR_bb0075","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40618-015-0241-7","article-title":"Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy","volume":"38","author":"Sisti","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/E161376.OR_bb0080","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/archophthalmol.2011.29","article-title":"Rundle and his curve","volume":"129","author":"Bartley","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.4158\/E161376.OR_bb0085","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1089\/thy.2013.0240","article-title":"Spontaneous improvement of untreated mild Graves' ophthalmopathy: Rundle's curve revisited","volume":"24","author":"Menconi","year":"2014","journal-title":"Thyroid"},{"key":"10.4158\/E161376.OR_bb0090","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/thy.1998.8.423","article-title":"Natural history of thyroid eye disease","volume":"8","author":"Perros","year":"1998","journal-title":"Thyroid"},{"key":"10.4158\/E161376.OR_bb0095","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","article-title":"Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center","volume":"98","author":"Tanda","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/E161376.OR_bb0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/E161376.OR_bb0105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/thy.2007.0315","article-title":"Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy","volume":"18","author":"Bartalena","year":"2008","journal-title":"Thyroid"},{"key":"10.4158\/E161376.OR_bb0110","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/thy.2012.0379","article-title":"Thyroid volume and severity of Graves' orbitopathy","volume":"23","author":"Profilo","year":"2013","journal-title":"Thyroid"},{"key":"10.4158\/E161376.OR_bb0115","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1210\/jc.2006-1800","article-title":"Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids","volume":"92","author":"Menconi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/E161376.OR_bb0120","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1210\/jc.2011-2077","article-title":"Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial","volume":"97","author":"Leo","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/E161376.OR_bb0125","first-page":"269","article-title":"Total thyroid ablation in Graves' Orbitopathy","volume":"172","author":"Menconi","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"10.4158\/E161376.OR_bb0130","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1210\/jc.2013-3093","article-title":"Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe graves' orbitopathy (GO): a prospective, randomized, single-blind clinical trial","volume":"99","author":"Moleti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/E161376.OR_bb0135","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves' orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.4158\/E161376.OR_bb0140","first-page":"198","article-title":"Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy","author":"Eckstein","year":"2010","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.4158\/E161376.OR_bb0145","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM198911163212001","article-title":"Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism","volume":"321","author":"Bartalena","year":"1989","journal-title":"N Engl J Med"},{"key":"10.4158\/E161376.OR_bb0150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","article-title":"Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy","volume":"338","author":"Bartalena","year":"1998","journal-title":"N Engl J Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20355671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20355671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:00:32Z","timestamp":1761516032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20355671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1530891X20355671"],"URL":"https:\/\/doi.org\/10.4158\/e161376.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variables Affecting the Long-Term Outcome of Graves Orbitopathy Following High-Dose Intravenous Glucocorticoid Pulse Therapy in Patients not Treated with Orbital Radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/E161376.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}